Atrial fibrillation, stroke, and quality of life

Annals of the New York Academy of Sciences

Volumn 1254, Issue 1, 2012, Pages 140-150

  Chinitz, Jason S ^a   Castellano, Jose M ^a   Kovacic, Jason C ^a   Fuster, Valentin ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Atrial fibrillation; Quality of life; Stroke; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; APIXABAN; ATOPAXAR; CLOPIDOGREL; DABIGATRAN ETEXILATE; IRBESARTAN; PURINERGIC P2Y12 RECEPTOR; RIVAROXABAN; TICAGRELOR; VORAPAXAR; WARFARIN;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ALZHEIMER DISEASE; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLEEDING; BRAIN HEMORRHAGE; BRAIN PERFUSION; CATHETER ABLATION; CLINICAL PRACTICE; COMORBIDITY; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG SAFETY; DYSPEPSIA; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FAILURE; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; LIVER FUNCTION TEST; LOW DRUG DOSE; META ANALYSIS (TOPIC); MORTALITY; MULTICENTER STUDY (TOPIC); PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PHASE 2 CLINICAL TRIAL (TOPIC); QT INTERVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; SELF MONITORING; SIDE EFFECT; SINUS RHYTHM; STENT THROMBOSIS; STROKE; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM; TREATMENT DURATION; UNITED STATES;

EID: 84860477233     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2012.06494.x     Document Type: Article

References (59)

1. Fuster, V. et al 2006. ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114: e257-e354.
2. Camm, A.J. et al 2010. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31: 2369-2429.
3. Friberg, L., N. Hammar & M. Rosenqvist 2010. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur. Heart J. 31: 967-975.
4. Roger, V.L. et al 2011. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 123: e18-e209.
5. Lin, H.J. et al 1996. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 27: 1760-1764.
6. Keogh, C., E. Wallace, C. Dillon, et al 2011. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis. Thromb. Haemost. 106: 528-538.
7. Krahn, A.D., J. Manfreda, R.B. Tate, et al 1995. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am. J. Med. 98: 476-484.
8. Wann, L.S. et al 2011. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 123: 1144-1150.
9. Fang, M.C. et al 2008. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J. Am. Coll. Cardiol. 51: 810-815.
10. Lip, G.Y. 2011. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. Am. J. Med. 124: 111-114.
11. Olesen, J.B. et al 2011. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 342: d124.
12. Bunch, T.J. et al 2010. Atrial fibrillation is independently associated with senile, vascular, and Alzheimer's dementia. Heart Rhythm 7: 433-437.
13. Ott, A. et al 1997. Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28: 316-321.
14. Forti, P. et al 2006. Atrial fibrillation and risk of dementia in non-demented elderly subjects with and without mild cognitive impairment. Neurol. Res. 28: 625-629.
15. Dublin, S. et al 2011. Atrial fibrillation and risk of dementia: a prospective cohort study. J. Am. Geriatr. Soc. 59: 1369-1375.
16. Sonnen, J.A. et al 2007. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Ann. Neurol. 62: 406-413.
17. Lavy, S. et al 1980. Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke 11: 35-38.
18. Fotuhi, M., V. Hachinski & P.J. Whitehouse 2009. Changing perspectives regarding late-life dementia. Nat. Rev. Neurol. 5: 649-658.
19. Schmidt, R. et al 2002. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol. 52: 168-174.
20. Crandall, M.A. et al 2009. Atrial fibrillation and CHADS2 risk factors are associated with highly sensitive C-reactive protein incrementally and independently. Pacin. Clin. Electrophysiol. 32: 648-652.
21. Bunch, T.J. et al 2011. Patients treated with catheter ablation for atrial fibrillation have long-term rates of death, stroke, and dementia similar to patients without atrial fibrillation. J. Cardiovasc. Electrophysiol. 22: 839-845.
22. Cairns, J.A. 1991. Stroke prevention in atrial fibrillation trial. Circulation 84: 933-935.
23. Hart, R.G. & J.L. Halperin 1999. Atrial fibrillation and thromboembolism: a decade of progress in stroke prevention. Ann. Intern. Med. 131: 688-695.
24. Wan, Y. et al 2008. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ. Cardiovasc. Qual. Outcomes 1: 84-91.
25. Wallentin, L. et al 2010. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376: 975-983.
26. O'Shea, S.I. et al 2008. Direct-to-patient expert system and home INR monitoring improves control of oral anticoagulation. J. Thromb. Thrombolysis 26: 14-21.
27. Heneghan, C., A. Ward & R. Perera 2012. Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 379: 322-334.
28. Wolf, P.A., R.D. Abbott & W.B. Kannel 1987. Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study. Arch. Intern. Med. 147: 1561-1564.
29. Fang, M.C. et al 2004. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann. Intern. Med. 141: 745-752.
30. Singer, D.E. et al 2009. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Intern. Med. 151: 297-305.
31. Connolly, S. et al 2006. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 367: 1903-1912.
32. Connolly, S.J. et al 2009. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N. Engl. J. Med. 360: 2066-2078.
33. Wann, L.S. et al 2011. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J. Am. Coll. Cardiol. 57: 223-242.
34. Wallentin, L. et al 2009. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361: 1045-1057.
35. Leonardi, S., P. Tricoci & R.C. Becker 2010. Thrombin receptor antagonists for the treatment of atherothrombosis: therapeutic potential of vorapaxar and E-5555. Drugs 70: 1771-1783.
36. Goto, S., H. Ogawa, M. Takeuchi, et al 2010. Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease. Eur. Heart J. 31: 2601-2613.
37. Paikin, J.S., D.S. Wright, M.A. Crowther, et al 2010. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation 121: 2067-2070.
38. Sourgounis, A., J. Lipiecki, T.S. Lo, & M. Hamon 2009. Coronary stents and chronic anticoagulation. Circulation 119: 1682-1688.
39. Schulz, S. et al 2009. Stent thrombosis after drug-eluting stent implantation: incidence, timing, and relation to discontinuation of clopidogrel therapy over a 4-year period. Eur. Heart J. 30: 2714-2721.
40. Berger, P.B. et al 2010. Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Circulation 121: 2575-2583.
41. Connolly, S.J. et al 2009. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 361: 1139-1151.
42. Patel, M.R. et al 2011. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N. Engl. J. Med. 365: 883-891.
43. Connolly, S.J. et al 2011. Apixaban in patients with atrial fibrillation. N. Engl. J. Med. 364: 806-817.
44. Granger, C.B., J.H. Alexander, J.J.V. McMurray, et al 2011. Apixaban versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 365: 981-992.
45. Stoddard, M.F., P.R. Dawkins, C.R. Prince & N.M. Ammash 1995. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. J. Am. Coll. Cardiol. 25: 452-459.
46. Holmes, D.R. et al 2009. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374: 534-542.
47. Reddy, V.Y., D. Holmes, S.K. Doshi, et al 2011. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. Circulation 123: 417-424.
48. Singh, S.M., S.R. Dukkipati, A. d'Avila, et al 2010. Percutaneous left atrial appendage closure with an epicardial suture ligation approach: a prospective randomized pre-clinical feasibility study. Heart Rhythm 7: 370-376.
49. Bruce, C.J. et al 2011. Percutaneous epicardial left atrial appendage closure: intermediate-term results. J. Cardiovasc. Electrophysiol. 22: 64-70.
50. Wyse, D.G. et al 2002. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347: 1825-1833.
51. Van Gelder, I.C. et al 2002. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347: 1834-1840.
52. Hohnloser, S.H., K.H. Kuck & J. Lilienthal 2000. Rhythm or rate control in atrial fibrillation-Pharmacological intervention in atrial fibrillation (PIAF): a randomised trial. Lancet 356: 1789-1794.
53. Opolski, G. et al 2004. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 126: 476-486.
54. Carlsson, J. et al 2003. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol. 41: 1690-1696.
55. Roy, D. et al 2008. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358: 2667-2677.
56. Corley, S.D. et al 2004. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation 109: 1509-1513.
57. Wilber, D.J. et al 2010. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA 303: 333-340.
58. Pappone, C. et al 2006. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study. J. Am. Coll. Cardiol. 48: 2340-2347.
59. Hunter, R.J. et al 2012. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. Heart 98: 48-53.